+关注
HENGLM003
暂无个人介绍
IP属地：未知
8
关注
0
粉丝
0
主题
0
勋章
主贴
热门
HENGLM003
2021-12-24
Like
抱歉，原内容已删除
HENGLM003
2021-12-24
Like
Singapore stocks to watch: Sembmarine, CICT, Mapletree Industrial Trust, Frasers Property, mDR
HENGLM003
2021-12-24
Like
抱歉，原内容已删除
HENGLM003
2021-12-24
Like
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3559084161237277,"uuid":"3559084161237277","gmtCreate":1595991001567,"gmtModify":1595991001567,"name":"HENGLM003","pinyin":"henglm003","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":698370142,"gmtCreate":1640310920692,"gmtModify":1640313104768,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698370142","repostId":"1154370846","repostType":4,"isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698370943,"gmtCreate":1640310899557,"gmtModify":1640313017933,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698370943","repostId":"1123192179","repostType":4,"repost":{"id":"1123192179","pubTimestamp":1640306381,"share":"https://www.laohu8.com/m/news/1123192179?lang=&edition=full","pubTime":"2021-12-24 08:39","market":"sg","language":"en","title":"Singapore stocks to watch: Sembmarine, CICT, Mapletree Industrial Trust, Frasers Property, mDR","url":"https://stock-news.laohu8.com/highlight/detail?id=1123192179","media":"businesstimes","summary":"THE following companies saw new developments that may affect trading of their securities on Friday (","content":"<div>\n<p>THE following companies saw new developments that may affect trading of their securities on Friday (Dec 24):\nSembcorp Marine (Sembmarine): Its wholly-owned subsidiary Jurong Shipyard will be defending...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr\">Web Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore stocks to watch: Sembmarine, CICT, Mapletree Industrial Trust, Frasers Property, mDR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore stocks to watch: Sembmarine, CICT, Mapletree Industrial Trust, Frasers Property, mDR\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 08:39 GMT+8 <a href=https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>THE following companies saw new developments that may affect trading of their securities on Friday (Dec 24):\nSembcorp Marine (Sembmarine): Its wholly-owned subsidiary Jurong Shipyard will be defending...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ME8U.SI":"丰树工业信托","STI.SI":"富时新加坡海峡指数","A27.SI":"MDR LIMITED","TQ5.SI":"星狮地产有限公司","C38U.SI":"凯德商用新加坡信托"},"source_url":"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123192179","content_text":"THE following companies saw new developments that may affect trading of their securities on Friday (Dec 24):\nSembcorp Marine (Sembmarine): Its wholly-owned subsidiary Jurong Shipyard will be defending its interests in 4 arbitration proceedings from a vendor over equipment supply invoices amounting to US$76 million, announced the group on Friday. Shares of Sembmarine closed S$0.001 or 1.2 per cent higher at S$0.082 on Thursday (Dec 23), before the news.\nCapitaLand Integrated Commercial Trust (CICT): Its manager has entered into an agreement to acquire a 50 per cent interest in an integrated development in Sydney, Australia for A$422 million (S$409.3 million). The move comes shortly after CICT acquired 2 office buildings for A$330.7 million earlier this month, as it looks to make further inroads into Australia. Units of CICT closed up S$0.01 or 0.5 per cent at S$1.98 before the announcement on Thursday.\nMapletree Industrial Trust (MIT): Its manager announced that the real estate investment trust has agreed to sell an industrial building at 19 Changi South Street 1 to Esco Micro at a proposed price of S$13 million in cash. The property is held by Mapletree Singapore Industrial Trust, a wholly-owned subsidiary of MIT. The counter closed at S$2.65 before the announcement on Thursday, up S$0.01 or 0.4 per cent.\nFrasers Property: The multinational property company revealed on Thursday that its joint venture (JV) for a potential investment in a land hasfallen through. Last month, it said its wholly-owned unit had entered into a framework agreement with an unnamed JV partner to participate in a potential investment in land. The counter closed flat at S$1.14 on Thursday before the announcement.\nmDR: The after-market service provider for consumer mobile products has fired its group chief operating officer Richard Siau amid police and company investigations into suspected misconduct. This followed an announcement on Dec 18, that it discovered 2 separate cases of unauthorised use of the group's marketing incentive rebates at its subsidiaries - 3 Mobile Telecom, A-Mobile and Handphoneshop. Shares of mDR closed up S$0.002, or 3 per cent, at S$0.068 before the announcement on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698344786,"gmtCreate":1640310793165,"gmtModify":1640312275618,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698344786","repostId":"1125729979","repostType":4,"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698344170,"gmtCreate":1640310734720,"gmtModify":1640311665606,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698344170","repostId":"1120769352","repostType":4,"isVote":1,"tweetType":1,"viewCount":733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698344170,"gmtCreate":1640310734720,"gmtModify":1640311665606,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698344170","repostId":"1120769352","repostType":4,"repost":{"id":"1120769352","pubTimestamp":1640309702,"share":"https://www.laohu8.com/m/news/1120769352?lang=&edition=full","pubTime":"2021-12-24 09:35","market":"sg","language":"en","title":"Singapore stocks rise at Friday's open; STI up 0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120769352","media":"businesstimes","summary":"SINGAPORE shares rose in early trade on Friday (Dec 24), following extended rallies on Wall Street o","content":"<div>\n<p>SINGAPORE shares rose in early trade on Friday (Dec 24), following extended rallies on Wall Street over optimism on the Omicron Covid-19 variant.\nThe Straits Times Index (STI) moved up 0.1 per cent or...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/singapore-stocks-rise-at-fridays-open-sti-up-01-0\">Web Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore stocks rise at Friday's open; STI up 0.1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore stocks rise at Friday's open; STI up 0.1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 09:35 GMT+8 <a href=https://www.businesstimes.com.sg/stocks/singapore-stocks-rise-at-fridays-open-sti-up-01-0><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE shares rose in early trade on Friday (Dec 24), following extended rallies on Wall Street over optimism on the Omicron Covid-19 variant.\nThe Straits Times Index (STI) moved up 0.1 per cent or...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/singapore-stocks-rise-at-fridays-open-sti-up-01-0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.businesstimes.com.sg/stocks/singapore-stocks-rise-at-fridays-open-sti-up-01-0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120769352","content_text":"SINGAPORE shares rose in early trade on Friday (Dec 24), following extended rallies on Wall Street over optimism on the Omicron Covid-19 variant.\nThe Straits Times Index (STI) moved up 0.1 per cent or 3.86 points to 3,100.67 as at 9.01 am.\nGainers outnumbered losers 68 to 24, after 25.4 million securities worth S$19 million changed hands.\nQT Vascular was the most traded in terms of volume as at 9.03 am, gaining S$0.001 or 33.3 per cent to S$0.004 after 3.9 million shares were traded. This comes after the medtech company said on Wednesday (Dec 22) that its requisitioning shareholders have dropped the attempt to call for a third extraordinary general meeting to appoint new directors - the latest development in an ongoing boardroom tussle.\nDigital security firm DiSa was also actively traded at the open, unchanged at S$0.005, with 3.5 million shares changing hands.\nIndex counter Thai Beverage was among the most actively traded securities, flat at S$0.66 after 1.8 million shares were traded.\nThe trio of local banks rose in early trade. DBS inched S$0.01 or 0.03 per cent higher to S$32.51, UOB advanced S$0.06 or 0.2 per cent to S$26.79, while OCBC gained S$0.03 or 0.3 per cent to S$11.34 as at 9.04 am.\nOver on Wall Street, the S&P 500 concluded a strong holiday-shortened week by setting a record on Thursday (Dec 23), extending a rally amid optimism that the Omicron Covid-19 variant will not significantly weigh on growth.\nThe broad-based S&P 500 index piled on 0.6 per cent to finish at 4,725.79, overtaking a previous record set earlier this month and ending with a 2.3 per cent gain for the week.\nThe Dow Jones Industrial Average climbed 0.5 per cent to close at 35,950.56, while the tech-rich Nasdaq Composite Index jumped 0.8 per cent to 15,653.37.\nMeanwhile, European shares hit a 1-month high on Thursday, as signs that the impact of the Omicron Covid-19 variant may be less severe than feared led to improved risk appetite.\nThe pan-European Stoxx 600 gained 1 per cent to close at 483.01, marking the third straight session of gains.\nElsewhere in Asia, Tokyo stocks opened higher on Friday, extending US rallies.\nThe benchmark Nikkei 225 index was up 0.2 per cent or 59.63 points at 28,858.00 in early trade, while the broader Topix index edged up 0.3 per cent or 5.59 points to 1,995.02.","news_type":1},"isVote":1,"tweetType":1,"viewCount":733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698370943,"gmtCreate":1640310899557,"gmtModify":1640313017933,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698370943","repostId":"1123192179","repostType":4,"repost":{"id":"1123192179","pubTimestamp":1640306381,"share":"https://www.laohu8.com/m/news/1123192179?lang=&edition=full","pubTime":"2021-12-24 08:39","market":"sg","language":"en","title":"Singapore stocks to watch: Sembmarine, CICT, Mapletree Industrial Trust, Frasers Property, mDR","url":"https://stock-news.laohu8.com/highlight/detail?id=1123192179","media":"businesstimes","summary":"THE following companies saw new developments that may affect trading of their securities on Friday (","content":"<div>\n<p>THE following companies saw new developments that may affect trading of their securities on Friday (Dec 24):\nSembcorp Marine (Sembmarine): Its wholly-owned subsidiary Jurong Shipyard will be defending...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr\">Web Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore stocks to watch: Sembmarine, CICT, Mapletree Industrial Trust, Frasers Property, mDR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore stocks to watch: Sembmarine, CICT, Mapletree Industrial Trust, Frasers Property, mDR\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 08:39 GMT+8 <a href=https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>THE following companies saw new developments that may affect trading of their securities on Friday (Dec 24):\nSembcorp Marine (Sembmarine): Its wholly-owned subsidiary Jurong Shipyard will be defending...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ME8U.SI":"丰树工业信托","STI.SI":"富时新加坡海峡指数","A27.SI":"MDR LIMITED","TQ5.SI":"星狮地产有限公司","C38U.SI":"凯德商用新加坡信托"},"source_url":"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sembmarine-cict-mapletree-industrial-trust-frasers-property-mdr","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123192179","content_text":"THE following companies saw new developments that may affect trading of their securities on Friday (Dec 24):\nSembcorp Marine (Sembmarine): Its wholly-owned subsidiary Jurong Shipyard will be defending its interests in 4 arbitration proceedings from a vendor over equipment supply invoices amounting to US$76 million, announced the group on Friday. Shares of Sembmarine closed S$0.001 or 1.2 per cent higher at S$0.082 on Thursday (Dec 23), before the news.\nCapitaLand Integrated Commercial Trust (CICT): Its manager has entered into an agreement to acquire a 50 per cent interest in an integrated development in Sydney, Australia for A$422 million (S$409.3 million). The move comes shortly after CICT acquired 2 office buildings for A$330.7 million earlier this month, as it looks to make further inroads into Australia. Units of CICT closed up S$0.01 or 0.5 per cent at S$1.98 before the announcement on Thursday.\nMapletree Industrial Trust (MIT): Its manager announced that the real estate investment trust has agreed to sell an industrial building at 19 Changi South Street 1 to Esco Micro at a proposed price of S$13 million in cash. The property is held by Mapletree Singapore Industrial Trust, a wholly-owned subsidiary of MIT. The counter closed at S$2.65 before the announcement on Thursday, up S$0.01 or 0.4 per cent.\nFrasers Property: The multinational property company revealed on Thursday that its joint venture (JV) for a potential investment in a land hasfallen through. Last month, it said its wholly-owned unit had entered into a framework agreement with an unnamed JV partner to participate in a potential investment in land. The counter closed flat at S$1.14 on Thursday before the announcement.\nmDR: The after-market service provider for consumer mobile products has fired its group chief operating officer Richard Siau amid police and company investigations into suspected misconduct. This followed an announcement on Dec 18, that it discovered 2 separate cases of unauthorised use of the group's marketing incentive rebates at its subsidiaries - 3 Mobile Telecom, A-Mobile and Handphoneshop. Shares of mDR closed up S$0.002, or 3 per cent, at S$0.068 before the announcement on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698344786,"gmtCreate":1640310793165,"gmtModify":1640312275618,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698344786","repostId":"1125729979","repostType":4,"repost":{"id":"1125729979","pubTimestamp":1640304436,"share":"https://www.laohu8.com/m/news/1125729979?lang=&edition=full","pubTime":"2021-12-24 08:07","market":"sg","language":"en","title":"Singapore Stock Market Has A Green Light For Friday's Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=1125729979","media":"RTTNews","summary":"The Singapore stock market has finished higher in three straight sessions, gathering almost 25 point","content":"<p>The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau and it may extend its gains on Friday.</p>\n<p>The global forecast for the Asian markets is upbeat on easing virus concerns, rising crude oil prices and solid economic data. The European and U.S. markets were up and the Asian markets are expected to open in similar fashion.</p>\n<p>The STI finished modestly higher on Thursday following gains from the financial shares, property stocks and plantations.</p>\n<p>For the day, the index rose 9.30 points or 0.30 percent to finish at 3,096.81 after trading between 3,090.25 and 3,104.18. Volume was 878.5 million shares worth S$515.8 million. There were 265 gainers and 169 decliners.</p>\n<p>Among the actives, Ascendas REIT fell 0.34 percent, while CapitaLand Integrated Commercial Trust and Mapletree Commercial Trust both gained 0.51 percent, City Developments jumped 0.76 percent, Comfort DelGro climbed 0.74 percent, Dairy Farm International surged 2.23 percent, DBS Group increased 0.37 percent, Genting Singapore advanced 0.66 percent, Hongkong Land rallied 1.17 percent, Keppel Corp rose 0.39 percent, Mapletree Logistics Trust added 0.54 percent, Oversea-Chinese Banking Corporation collected 0.44 percent, SATS accelerated 1.32 percent, SembCorp Industries shed 0.50 percent, Singapore Airlines spiked 1.45 percent, Singapore Exchange was up 0.11 percent, Singapore Press Holdings lost 0.43 percent, Thai Beverage sank 0.75 percent, Wilmar International soared 1.50 percent and Yangzijiang Shipbuilding, Singapore Technologies Engineering, United Overseas Bank and SingTel were unchanged.</p>\n<p>The lead from Wall Street is positive as the major averages opened higher on Thursday and remained comfortably in the green throughout the session, ending near record highs.</p>\n<p>The Dow jumped 196.67 points or 0.55 percent to finish at 35,950.56, while the NASDAQ climbed 131.48 points or 0.85 percent to close at 15,653.37 and the S&P 500 rose 29.23 points or 0.62 percent to end at 4,725.79. For the holiday-shortened week, the NASDAQ spiked 3.2 percent, the S&P improved 2.3 percent and the Dow gained 1.7 percent.</p>\n<p>Easing concerns about the Omicron variant of the coronavirus contributed to the continued strength on Wall Street, as separate studies have indicated the new strain poses a lower risk of severe disease and hospitalization than the Delta variant.</p>\n<p>Traders were also reacting to a slew of economic data, including a Labor Department report showing first-time claims for U.S. jobless benefits came in flat last week. Also, the Commerce Department said new orders for U.S. manufactured durable goods spiked much more than expected in November.</p>\n<p>Meanwhile, the Commerce Department also noted a continued acceleration in the pace of core consumer price growth last month, and also that new home sales skyrocketed.</p>\n<p>Crude oil futures extended gains to a third straight day amid hopes about outlook for energy demand as concerns about Omicron variant of the coronavirus faded. West Texas Intermediate Crude oil futures for February ended higher by $1.03 or 1.4 percent at $73.79 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stock Market Has A Green Light For Friday's Trade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stock Market Has A Green Light For Friday's Trade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 08:07 GMT+8 <a href=https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau ...</p>\n\n<a href=\"https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125729979","content_text":"The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau and it may extend its gains on Friday.\nThe global forecast for the Asian markets is upbeat on easing virus concerns, rising crude oil prices and solid economic data. The European and U.S. markets were up and the Asian markets are expected to open in similar fashion.\nThe STI finished modestly higher on Thursday following gains from the financial shares, property stocks and plantations.\nFor the day, the index rose 9.30 points or 0.30 percent to finish at 3,096.81 after trading between 3,090.25 and 3,104.18. Volume was 878.5 million shares worth S$515.8 million. There were 265 gainers and 169 decliners.\nAmong the actives, Ascendas REIT fell 0.34 percent, while CapitaLand Integrated Commercial Trust and Mapletree Commercial Trust both gained 0.51 percent, City Developments jumped 0.76 percent, Comfort DelGro climbed 0.74 percent, Dairy Farm International surged 2.23 percent, DBS Group increased 0.37 percent, Genting Singapore advanced 0.66 percent, Hongkong Land rallied 1.17 percent, Keppel Corp rose 0.39 percent, Mapletree Logistics Trust added 0.54 percent, Oversea-Chinese Banking Corporation collected 0.44 percent, SATS accelerated 1.32 percent, SembCorp Industries shed 0.50 percent, Singapore Airlines spiked 1.45 percent, Singapore Exchange was up 0.11 percent, Singapore Press Holdings lost 0.43 percent, Thai Beverage sank 0.75 percent, Wilmar International soared 1.50 percent and Yangzijiang Shipbuilding, Singapore Technologies Engineering, United Overseas Bank and SingTel were unchanged.\nThe lead from Wall Street is positive as the major averages opened higher on Thursday and remained comfortably in the green throughout the session, ending near record highs.\nThe Dow jumped 196.67 points or 0.55 percent to finish at 35,950.56, while the NASDAQ climbed 131.48 points or 0.85 percent to close at 15,653.37 and the S&P 500 rose 29.23 points or 0.62 percent to end at 4,725.79. For the holiday-shortened week, the NASDAQ spiked 3.2 percent, the S&P improved 2.3 percent and the Dow gained 1.7 percent.\nEasing concerns about the Omicron variant of the coronavirus contributed to the continued strength on Wall Street, as separate studies have indicated the new strain poses a lower risk of severe disease and hospitalization than the Delta variant.\nTraders were also reacting to a slew of economic data, including a Labor Department report showing first-time claims for U.S. jobless benefits came in flat last week. Also, the Commerce Department said new orders for U.S. manufactured durable goods spiked much more than expected in November.\nMeanwhile, the Commerce Department also noted a continued acceleration in the pace of core consumer price growth last month, and also that new home sales skyrocketed.\nCrude oil futures extended gains to a third straight day amid hopes about outlook for energy demand as concerns about Omicron variant of the coronavirus faded. West Texas Intermediate Crude oil futures for February ended higher by $1.03 or 1.4 percent at $73.79 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698370142,"gmtCreate":1640310920692,"gmtModify":1640313104768,"author":{"id":"3559084161237277","authorId":"3559084161237277","name":"HENGLM003","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698370142","repostId":"1154370846","repostType":4,"repost":{"id":"1154370846","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640299823,"share":"https://www.laohu8.com/m/news/1154370846?lang=&edition=full","pubTime":"2021-12-24 06:50","market":"us","language":"en","title":"U.S. authorizes Merck pill as second at-home COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1154370846","media":"Reuters","summary":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 fo","content":"<p>Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc.</p>\n<p>The U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.</p>\n<p>The drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.</p>\n<p>The authorization allows use of the drug for mild-to-moderate COVID-19 and along with the Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.</p>\n<p>Pfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.</p>\n<p>The FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.</p>\n<p>Merck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.</p>\n<p>Availability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.</p>\n<p>The FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.</p>\n<p>FDA official John Farley said during a press briefing that GlaxoSmithKline's and Vir Biotech's antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.</p>\n<p>Merck said that its treatment had advantages over the Pfizer pill.</p>\n<p>\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.</p>\n<p>\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.</p>\n<p>Nearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.</p>\n<p>Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.</p>\n<p>Some of the FDA's experts have said that could lead to more troublesome variants.</p>\n<p>There have also been some safety concerns around the drug because it may affect bone cartilage and growth.</p>\n<p>Due to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.</p>\n<p>The agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.</p>\n<p>The drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.</p>\n<p>The U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.</p>\n<p>Merck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Merck pill as second at-home COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Merck pill as second at-home COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc.</p>\n<p>The U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.</p>\n<p>The drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.</p>\n<p>The authorization allows use of the drug for mild-to-moderate COVID-19 and along with the Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.</p>\n<p>Pfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.</p>\n<p>The FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.</p>\n<p>Merck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.</p>\n<p>Availability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.</p>\n<p>The FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.</p>\n<p>FDA official John Farley said during a press briefing that GlaxoSmithKline's and Vir Biotech's antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.</p>\n<p>Merck said that its treatment had advantages over the Pfizer pill.</p>\n<p>\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.</p>\n<p>\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.</p>\n<p>Nearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.</p>\n<p>Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.</p>\n<p>Some of the FDA's experts have said that could lead to more troublesome variants.</p>\n<p>There have also been some safety concerns around the drug because it may affect bone cartilage and growth.</p>\n<p>Due to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.</p>\n<p>The agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.</p>\n<p>The drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.</p>\n<p>The U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.</p>\n<p>Merck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154370846","content_text":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc.\nThe U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.\nThe drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.\nThe authorization allows use of the drug for mild-to-moderate COVID-19 and along with the Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.\nPfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.\nThe FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.\nMerck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.\nAvailability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.\nThe FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.\nFDA official John Farley said during a press briefing that GlaxoSmithKline's and Vir Biotech's antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.\nMerck said that its treatment had advantages over the Pfizer pill.\n\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.\n\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.\nNearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.\nMerck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.\nSome of the FDA's experts have said that could lead to more troublesome variants.\nThere have also been some safety concerns around the drug because it may affect bone cartilage and growth.\nDue to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.\nThe agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.\nThe drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.\nThe U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.\nMerck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.","news_type":1},"isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
